ANKRD22 Drives Rapid Proliferation of Lgr5+ Cells and Acts as a Promising Therapeutic Target in Gastric Mucosal Injury

Jingwen Liu,Jingni Wu,Rui Wang,Dandan Zhong,Yiqing Qiu,Hongping Wang,Zhenya Song,Yongliang Zhu
DOI: https://doi.org/10.1016/j.jcmgh.2021.06.020
IF: 8.797
2021-01-01
Cellular and Molecular Gastroenterology and Hepatology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background &amp; aims</h3><p>Rapid gastric epithelial progenitor cell (EPC) proliferation and inflammatory response inhibition play key roles in promoting the repair of gastric mucosal damage. However, specific targets inducing these effects are unknown. In this study, we explored the effects of a potential target, Ankyrin repeat domain 22 (ANKRD22).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>An acute gastric mucosal injury model was established with <em>Ankrd22</em><sup><em>-/-</em></sup> and <em>Ankrd22</em><sup>+/+</sup> mice by intragastric administration of acidified ethanol. Organoid culture and flow cytometry were performed to evaluate the effects of ANKRD22 on Lgr5<sup>+</sup> gastric EPC proliferation. The mechanisms by which ANKRD22 affects gastric EPC proliferation and inflammatory responses were explored by mitochondrial Ca<sup>2+</sup> influx and immunoblotting. Candidate ANKRD22 inhibitors were then virtually screened and validated <em>in vitro</em> and <em>in vivo</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>After acute gastric mucosal injury, the number of Lgr5<sup>+</sup> gastric EPCs was significantly increased in <em>Ankrd22</em><sup><em>-/-</em></sup> mice compared with that in <em>Ankrd22</em><sup><em>+/+</em></sup> mice. Moreover, <em>Ankrd22</em> knockout attenuated inflammatory cell infiltration into damaged gastric tissues. <em>ANKRD22</em> deletion also reduced mitochondrial Ca<sup>2+</sup> influx and cytoplasmic NFAT in gastric epithelial cells and macrophages, which further induced Lgr5<sup>+</sup> gastric EPC proliferation and decreased macrophage release of TNF-α and IL-1α. Additionally, a small molecule, AV023, was found to display effects similar to those produced by <em>ANKRD22</em> deletion <em>in vitro.</em> Intraperitoneal injection of AV023 into the mouse model promoted the repair of gastric mucosal damage, with increased proliferation of Lgr5<sup>+</sup> gastric EPCs and visible relief of inflammation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>ANKRD22 inhibition is a potential target-based therapeutic approach for promoting the repair of gastric mucosal damage.</p>
gastroenterology & hepatology
What problem does this paper attempt to address?